Effects of pegfilgrastim on normal biodistribution of 18F-FDG: Preclinical and clinical studies

Journal of Nuclear Medicine

Volumn 47, Issue 6, 2006, Pages 950-956

  Jacene, Heather A ^a   Ishimori, Takayoshi ^a   Engles, James M ^a   Leboulleux, Sophie ^a   Stearns, Vered ^b   Wahl, Richard L ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

18F FDG; Bone marrow; G CSF; Pegfilgrastim; Positron

Indexed keywords

DOCETAXEL; FLUORODEOXYGLUCOSE F 18; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; DIAGNOSTIC AGENT; IMMUNOSUPPRESSIVE AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT THERAPY; ADULT; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG MECHANISM; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ANIMAL; ANTIBODY SPECIFICITY; BREAST TUMOR; DRUG EFFECT; DRUG SCREENING; LEWIS RAT; METABOLIC CLEARANCE RATE; METABOLISM; PILOT STUDY; REFERENCE VALUE; RETROSPECTIVE STUDY; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; BREAST NEOPLASMS; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; FEMALE; FILGRASTIM; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; PILOT PROJECTS; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; REFERENCE VALUES; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION;

EID: 33746101886     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23:4652-4661.
2. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 2003; 44:224-239.
3. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B. Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111.
4. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors: biology and clinical applications. N Engl J Med. 1989;321:1449-1459.
5. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med. 1992;327:28-35.
6. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med. 1992;327:99-106.
7. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170.
8. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29-35.
9. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727-731.
10. Molineux G, Kinstler O, Briddell B, et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol. 1999;27:1724-1734.
11. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522-2528.
12. Hollinger EF, Alibazoglu H, Ali A, Green A, Lamonica G. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23:93-98.
13. Yao WJ, Hoh CK, Hawkins RA, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995;36: 794-799.
14. Knopp MV, Bischoff H, Rimac A, Oberdorfer F, Van Kaick G. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol. 1996;23:845-849.
15. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173-180.
16. Sugawara Y, Zasadny KR, Kison PV, Baker LH, Wahl RL. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med. 1999;40:1456-1462.
17. Glaspy JA, Golde DW. Granulocyte colony-stimulating factor (G-CSF): preclinical and clinical studies. Semin Oncol. 1992;19:386-394.
18. Litam PP, Friedman HD, Loughran TP Jr. Splenic extramedullar hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor. Ann Intern Med. 1993;118:954-955.
19. Tsoi WC, To KF, Feng CS. Splenic hematopoiesis after granulocyte-colony stimulating factor therapy in a lupus patient. Am J Hematol. 1996;53:283-284.
20. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging. 2003;30:274-280.
21. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-388.
22. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 1996;56:1296-1302.
23. Jover R, Bort R, Gomez-Lechon MJ, Castell J. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology. 2001;33:668-675.
24. Iwahori T, Matsuura T, Maehashi H, et al. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology. 2003;37:665-673.
25. Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A. 1997;94:13209-13214.